Cargando…
A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics
Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301669/ https://www.ncbi.nlm.nih.gov/pubmed/34297759 http://dx.doi.org/10.1371/journal.pone.0254944 |